Brief: Pharming Group Expects 2026 Revenue At $405-$425 Mln
03/02/2026 06:09
Feb 3 (Reuters) - Pharming Group NV PHAR.AS: ANNOUNCES 2026 FINANCIAL GUIDANCE AND HIGHLIGHTS RARE DISEASE PIPELINE AT INVESTOR DAY 2026 REVENUE GUIDANCE OF $405-$425 MILLION 2026 OPERATING EXPENSE GUIDANCE OF $330-$335 MILLION Source text: ID:nGNX8jnfrf Further company coverage: PHAR.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))